|Home | About | Journals | Submit | Contact Us | Français|
The CC chemokine receptor 5 (CCR5) has been shown to be important in the recruitment of T-helper cells to the synovium, where they accumulate, drive the inflammatory process and the consequent synovitis and joint destruction. A 32 base-pair insertion/deletion variant (CCR5Δ32) within the gene leads to a frame shift and a nonfunctional receptor. CCR5Δ32 has been investigated for its association with juvenile idiopathic arthritis (JIA), with conflicting results. The aim of this study was to investigate whether CCR5Δ32 is associated with JIA in an UK population. CCR5Δ32 was genotyped in JIA cases (n=1054) and healthy controls (n=3129) and genotype and allele frequencies were compared. A meta-analysis of our study combined with previously published studies was performed. CCR5Δ32 was significantly associated with protection from developing JIA, in this UK data set (Ptrend=0.006, odds ratio (OR) 0.79 95% confidence interval (95% CI): 0.66–0.94). The meta-analysis of all published case–control association studies confirmed the protective association with JIA (P=0.001 OR 0.82 95% CI: 0.73–0.93). CCR5Δ32 is a functional variant determining the number of receptors on the surface of T cells, and it is hypothesized that the level of CCR5 expression could influence the migration of proinflammatory T cells into the synovium and thus susceptibility to JIA.
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease of childhood. It is defined as chronic inflammation of the synovial joints, with unknown etiology, which starts before the age of 16 years and persists for at least 6 weeks. There is a wealth of evidence to suggest that the pathogenesis is largely driven by T cells.1 It has been shown that there is a strong bias in the overall T-helper (Th) 1 cytokine profile of synovial fluid (SF) T cells compared with peripheral blood T cells from patients with either oligoarticular or polyarticular JIA, and it is proposed that this polarization may be caused by selective recruitment by chemokine receptor expression.2 CC chemokine receptor 5 (CCR5) is predominantly found on monocytes and T cells, particularly of the Th1 phenotype.3 Its function is in the recruitment of these Th1 T cells to the synovium, where they accumulate and produce proinflammatory cytokines, such as interleukin-2 (IL2) and interferon-γ (which drives the inflammatory process and the consequent synovitis and joint destruction). CCR5 binds a number of proinflammatory chemokines, including CC chemokines, such as CCL3 (also known as macrophage inflammatory protein 1α), CCL4 (macrophage inflammatory protein β) and CCL5 (also known as regulated on activation, normal T-cell expressed and secreted).4 These chemokines have been found at high levels in the SF of patients with adult rheumatoid arthritis (RA),5 suggesting that CCR5+ T cells selectively accumulate in the SF in response to the presence of these chemokines. Furthermore, it has also been noted that the cell-surface CCR5 density determines the intensity of T-cell migration toward RA synoviocytes and also their stimulation by CCL5.6 Thus, the level of CCR5 expression could favor the inflammatory effect of intra-articular T cells by facilitating their recruitment and increasing their response to chemokines. Therefore, the density of CCR5 on cells may be predictive of disease severity.
The CCR5 gene on chromosome 3p21.3 contains a 32 base-pair insertion/deletion variant (CCR5Δ32), which leads to a frame shift and a nonfunctional receptor. Homozygosity for CCR5Δ32 results in a complete lack of surface expression of CCR5, whereas heterozygotes express low densities of cell-surface CCR5 compared with individuals homozygous for the wild-type CCR5 gene.7 The polymorphism has been extensively studied in RA with conflicting evidence for a protective association of the CCR5Δ32 polymorphism.8, 9, 10, 11, 12 However, a large meta-analysis of five case–control association studies confirmed the protective association between CCR5Δ32 and RA (odds ratio (OR) 0.65 95% confidence interval (95% CI): 0.55–0.77, P<0.0001).13 In JIA, again, the results are conflicting; one study reported that the CCR5Δ32 variant was protectively associated with JIA;14 another described no association;15 and a third found that the CCR5Δ32 variant was associated with JIA susceptibility.16 The aim of this study was to investigate whether CCR5Δ32 is associated with JIA in an UK population and to combine the results with those obtained in previous studies by meta-analysis.
Genotype counts conformed to Hardy–Weinberg expectations (P>0.05) in the control cohort. After quality control, 987 JIA samples and 3121 control samples were available for analysis. We found that the CCR5Δ32 variant was significantly associated with protection from developing JIA (Ptrend=0.006, OR 0.79 95% CI: 0.66–0.94) (Table 1).
Interestingly, the strongest protective effect was found in the rheumatoid factor-positive polyarthritis subtype (OR 0.41 95% CI: 0.18–0.93) (Table 2); however, there was no significant difference in allele frequencies across all the subtypes, suggesting that no subtype-specific associations exist.
To perform the meta-analysis, allele and genotype data from previous studies in JIA were collated (Table 3). Three previous studies were identified from literature searches: one from the United States,14 the second, a study of Norwegian JIA cases and controls15 and finally a study of Brazilian JIA cases and controls.16 The US study was a family-based association analysis; hence for the meta-analysis, data collected from the parents and unaffected siblings were used as control data. Studies from the Unites States and Norway reported very similar control allele frequencies (10–11%). However, control allele frequencies in the Brazilian study by Scheibel et al. were very different (3.8%). This study was relatively small and reported association of the CCR5Δ32 variant with JIA susceptibility. Inclusion of this study in the meta-analysis resulted in a P-value of 0.04 for the Breslow–Day test, suggesting significant heterogeneity between the studies. In view of the heterogeneity, the meta-analysis was, therefore, restricted to cohorts of Northern European descent and the results from the Brazilian cohort were not included in the calculation of the pooled OR. The pooled OR for the UK, US and Norwegian studies (Breslow–Day P=0.74) was 0.82 95% CI: 0.73–0.93, P=0.001. The combined analysis had a slightly more significant P-value and tighter CIs than that found for our UK JIA study alone (Figure 1).
The results from this investigation and the meta-analysis of previous studies suggest that the CCR5Δ32 variant is associated with protection from developing JIA for individuals of Northern European descent. Our study was the largest to date to investigate this association and had >80% power to detect a protective OR of 0.75, similar to the effect size identified in the Prahalad meta-analysis for RA (OR=0.65).13 The meta-analysis highlights the need for large sample sizes to detect variants with a modest effect.
The US family-based association study of the CCR5Δ32 variant found no significant deviation of transmission of CCR5Δ32 in the combined cohort of probands with JIA. However, stratification by age at onset found that CCR5Δ32 was significantly undertransmitted to probands with early-onset JIA (<6 years). In the UK cohort, there was no evidence for a stronger effect in cases with a young age at onset (Ptrend=0.1, OR 0.83 95% CI: 0.66–1.04); in fact, those with an older age at onset showed a slightly stronger effect (Ptrend=0.03, OR 0.77 95% CI: 0.60–0.97).
The same protective association has been found in RA but, as with JIA, there have been some conflicting results; however, a meta-analysis of five case–control association studies confirmed the protective association between CCR5Δ32 and RA (OR 0.65 95% CI: 0.55–0.77, P<0.0001). This is further evidence for shared susceptibility loci for RA and JIA, and adds to the evidence from other loci, which are associated with both diseases (and often other autoimmune diseases as well), such as PTPN22, IL2/IL21 region, IL2RA, AFF3, STAT4, TRAF1/C5 and TNFAIP3.17, 18, 19 Indeed, the CCR5Δ32 variant has previously been associated with protection from developing both type I diabetes and celiac disease,20 suggesting a pan-autoimmune disease role.
The influence of CCR5Δ32 on the clinical course of RA has also been investigated, but again the evidence is often conflicting, with the most recent study finding that carriers of the deletion were protected from joint erosion, had less extra-articular manifestations and had lower cumulative C-reactive protein levels.21 However, a number of other studies have found no evidence for an association with disease severity or outcome.10, 22, 23 These discrepancies may arise as a result of differences in statistical power and methodologies used but, given the fact that CCR5 expression levels may be associated with severity, it would be interesting to investigate whether CCR5Δ32 has any effect on outcome in JIA. Data from the CAPS (Childhood Arthritis Prospective Study), a prospective inception cohort study of JIA cases, will be invaluable in exploring this hypothesis, but are insufficiently powered at present to undertake these investigations.
The observation that there are six JIA cases that are homozygous for CCR5Δ32 suggests that there may be some redundancy in the chemokine system and other receptors and ligands may have a role in the development of JIA. A previous study that found high expression of two chemokine receptors, CCR5 and CXCR3 on SF on T cells from 20 JIA patients compared with peripheral blood T cells also found some evidence of redundancy.2 In that study, one of the JIA patients was homozygous for CCR5Δ32 but was, perhaps surprisingly, of the more severe extended oligoarthritis subtype. This individual had high levels of CXCR3 on SF T cells and had a high interferon-γ:IL4 ratio in the cytokine stimulation assay. In most cases, SF T cells were double positive for CCR5 and CXCR3, but T cells can express one or the other. The different coexpression also suggests that the levels of these two receptors are regulated by different factors.
It has been proposed that CCR5 is important in the recruitment of Th1 T cells to the joint but also, interestingly, a number of studies have linked CCR5 to the IL2 pathway. For example, IL2 upregulates CCR5 expression in vivo and in vitro24, 25, 26 and rapamycin, a drug that disrupts IL2 receptor signaling, reduces CCR5 surface expression on T cells.27 A recent study found that CCR5Δ32/Δ32 donors of peripheral blood mononuclear cells stimulated by antiCD3/CD28 showed significantly less IL2 production than did noncarriers of the CCR5Δ32 mutation. They showed that CCR5 influenced IL2 transcript levels and also that CCR5 influenced the expression of IL2RA/CD25 on CD4+ T cells both in vitro and in vivo. There was evidence that these effects are mediated through the nuclear factor of activated T cell signaling pathway. CCR5 expression was also shown to promote T-cell proliferation after T-cell activation.28 This is fascinating in that the IL2 gene region19, 29 and IL2RA genes30 are also associated with JIA. Interestingly, in all three cases, the SNP in the gene/region is associated with protection from JIA.
In conclusion, we have presented evidence for a protective association of the CCR5Δ32 variant in an UK JIA case–control cohort, which is strengthened by combining data obtained from two previous studies in populations of Northern European descent by meta-analysis. Further investigation into how this gene contributes to JIA pathogenesis is now required.
DNA was available for 1054 UK Caucasian JIA patients (332 males and 715 females) from three sources: BSPAR (The British Society for Paediatric and Adolescent Rheumatology) National Repository of JIA (n=654); a group of UK Caucasian patients with long-standing JIA (n=201), described previously;31 and a third cohort collected as part of the CAPS, a prospective inception cohort study of JIA cases from five centers across the United Kingdom (n=199).32 JIA cases were classified according to the ILAR criteria33 (Supplementary Table 1). Healthy Caucasian control DNA samples (n=3129) were available from five centers in the United Kingdom as described previously:34 Manchester, Sheffield, Leeds, Aberdeen and Oxford (total control sample size after quality control=3121). All individuals were recruited with ethical approval and provided informed consent (North-west Multi-Centre Research Ethics Committee (MREC 99/8/84) and the University of Manchester Committee on the Ethics of Research on Human Beings).
The CCR5Δ32 variant (rs333) was genotyped using the Sequenom iPlex MassARRAY platform according to the manufacturer's instructions (Sequenom, San Diego, CA, USA; http://www.sequenom.com/). A 90% sample quality control rate and a 90% genotyping success rate were imposed on the analysis.
Power calculations were performed using QUANTO to calculate the prior probability of detecting association in the current sample size at the allele frequency and effect sizes were reported previously in other autoimmune diseases for this variant.14 Calculations assumed a log-additive model, an α value of 0.05 and an effect size of 0.75. Genotype and allele frequencies were compared between cases with JIA and controls using the Cochrane–Armitage trend test implemented in PLINK (http://pngu.mgh.harvard.edu/purcell/plink/),35 and allelic ORs and their 95% CIs were calculated. JIA is a phenotypically heterogeneous disease and can be classified into more clinically homogeneous diseases using the ILAR classification criteria.36 However, comparing each of the ILAR subtypes separately against controls would result in a large number of hypothesis tests. Therefore, we also examined whether there was evidence of a difference in allele frequencies between the seven ILAR subtypes. Differences between subtypes were assessed using χ2-tests on the 7 × 2 tables.
Published case–control association studies of CCR5Δ32 with JIA were identified using a PUBMED search. Genotype and allele frequencies were obtained from the published studies. A test for heterogeneity between cohorts was carried out using the Breslow–Day test, and the Cochran–Mantel–Haenszel test was used to perform a meta-analysis of the three cohorts.
This work was supported by the Arthritis Research UK: grant reference no: 17552. We thank David Strachan for facilitating access to the 1958 birth cohort. We acknowledge the use of genotype data from the British 1958 Birth Cohort DNA collection, funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/02. We acknowledge support from the NIHR Manchester Biomedical Research Council.
Childhood arthritis prospective study (CAPS):
Eileen Baildam, Lynsey Brown, Joanne Buckley, Alice Chieng, Joyce Davidson, Michael Eltringham, Helen Foster, Mark Friswell, Janet Gardner-Medwin, Paul Gilbert, Kimme Hyrich, Julie Jones, Sham Lal, Mark Lay, Carol Lydon, Alexandra Meijer, Vicki Price, Jane Sim, Maureen Todd, Peter Ward, Lucy Wedderburn.
University of Manchester1: Stephen Eyre, Anne Hinks, Laura J Gibbons, John Bowes, Edward Flynn, Paul Martin, Xiayi Ke, Rachelle Donn, Wendy Thomson, Anne Barton, Jane Worthington.
University of Leeds2: Stephen Martin, James I Robinson, Ann W Morgan, Paul Emery
University of Sheffield3: Anthony G Wilson
University of London4: Sophia Steer
University of Aberdeen5: Lynne Hocking, David M Reid
University of Oxford6: Pille Harrison, Paul Wordsworth
1arc-Epidemiology Unit, Stopford Building, The University of Manchester, Manchester, UK.
2Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, LS9 7TF.
3School of Medicine and Biomedical Sciences, The University of Sheffield, Sheffield S10 2JF.
4Clinical and Academic Rheumatology, Kings College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS.
5Bone Research Group, Department of Medicine and Therapeutics, University of Aberdeen, UK, AB25 2ZD
6University of Oxford Institute of Musculoskeletal Sciences, Botnar Research Centre, Oxford OX3 7LD, UK
British Society of Paediatric and Adolescent Rheumatology (BSPAR) Study Group:
M Abinum, MD, M Becker, MD, A Bell, MD, A Craft, MD, E Crawley, MD, J David, MD, H Foster, MD, J Gardener-Medwin, MD, J Griffin, MD, A Hall, MD, M Hall, MD, A Herrick, MD, P Hollingworth, MD, L Holt, MD, S Jones, MD, G Pountain, MD, C Ryder, MD, T Southwood, MD, I Stewart, MD, H Venning. L Wedderburn, MD, P Woo, MD and S Wyatt, MD.
The authors declare no conflict of interest.
Supplementary Information accompanies the paper on Genes and Immunity website (http://www.nature.com/gene)